Marex Group’s Titan Pharmaceuticals TTNP Stock Holding History

Marex Group’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,663	Closed	-$44.8K	–	1004
2025 Q2	$44.8K	Buy	+10,663	New	+$45.2K	﹤0.01%	602

Other funds holding TTNP

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GWSA

Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marex Group's TTNP Position: Q3 2025 in Review

Marex Group sold out of Titan Pharmaceuticals (TTNP) in Q3 2025, closing a stake of 10,663 shares — an estimated $44.8K sold.

Marex Group first reported a position in TTNP in Q2 2025 and held it in 1 quarter. The position peaked at $44.8K in Q2 2025. 18 funds tracked by Wall St. Rank hold TTNP as of Q3 2025.

Marex Group reported no remaining Titan Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Marex Group sold 10,663 Titan Pharmaceuticals shares in Q3 2025, an estimated $44.8K.
Marex Group first reported a position in Titan Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Marex Group's Titan Pharmaceuticals position peaked at $44.8K in Q2 2025.
18 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q3 2025.

Based on Marex Group's 13F filing for Q3 2025, filed 14 Nov 2025.